To celebrate the successful launch of DEX+ and its strategic partnership with pump.fun, MEXC is pleased to announce its ...

Pump.fun has launched its own decentralized exchange (DEX) called PumpSwap, potentially displacing Raydium as the primary ...

The Logitech G Pro X Superlight 2 Dex manages to combine comfort and speed in a way that many flagship gaming mice attempt but few actually achieve. Its contoured shape, excellent main clicks ...

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies. Matthew Matasar, MD, chief of the division of blood disorders at the ...

TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...

Regeneron Pharmaceuticals announced that the FDA has accepted for review its resubmission of the Biologics License Application (BLA) for odronextamab, a treatment for relapsed/refractory ...

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X. Forward-Looking Statements and Use of Digital Media This press release includes ...

Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with one of the most ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Wednesday said that the U.S. Food and Drug Administration (FDA) has accepted resubmission of the Biologics License Application (BLA) for ...

TARRYTOWN, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the ...